Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Jul;267(7):2083-2089.
doi: 10.1007/s00415-020-09807-2. Epub 2020 Mar 28.

Long-term outcomes in temporal lobe epilepsy with glutamate decarboxylase antibodies

Bastien Joubert #  1   2 , Aude Belbezier #  1 , Julie Haesebaert  3   4 , Sylvain Rheims  5   6 , François Ducray  1 , Géraldine Picard  1 , Véronique Rogemond  1   2 , Dimitri Psimaras  1   7 , Giulia Berzero  7 , Virginie Desestret  1   2 , Jérôme Honnorat  8   9   10
Affiliations

Long-term outcomes in temporal lobe epilepsy with glutamate decarboxylase antibodies

Bastien Joubert et al. J Neurol. 2020 Jul.

Abstract

Objective: To assess the long-term outcomes of patients with temporal lobe epilepsy and CSF anti-glutamate decarboxylase antibodies (GAD65-Abs).

Methods: We retrospectively analyzed the clinical records of 35 patients with temporal lobe epilepsy and CSF GAD65-Abs, collected from January 1993 to December 2016 and assessed cognitive impairment and seizure activity at last visit. Cognitive impairment was considered significant if impacting on daily life activities. Immunohistochemistry on rat brain slices and ELISA were used for antibody detection and titration.

Results: Median age was 30 years (range 2-63), 32/35 (91%) patients were female, and median follow-up was 68 months (range 7-232). At presentation, 20 patients had isolated temporal lobe epilepsy and 15 patients had other limbic symptoms, including anterograde amnesia (n = 10) and behavioral disturbances (n = 5). Progressive clinical deterioration over follow-up was reported in 28/35 patients (80%), including gradual increase of memory impairment (n = 25), and apparition of behavioral disturbances (n = 4) or mood disorders (n = 18). At last follow-up, 24/35 (69%) patients had cognitive disturbances with an impact on patient's daily life activities, and 28/35 (80%) still had active seizures.

Conclusion: Most patients with temporal lobe epilepsy and CSF GAD65-Abs develop a chronic disease with progressive cognitive impairment and refractory epilepsy regardless of the presence of additional limbic symptoms at onset.

Keywords: Anti-GAD65 antibodies; Autoimmune encephalitis; Cognition; Drug-resistant epilepsy; Temporal lobe epilepsy.

PubMed Disclaimer

References

    1. Dalakas MC, Fujii M, Li M, McElroy B (2000) The clinical spectrum of anti-GAD antibody-positive patients with stiff-person syndrome. Neurology 55:1531–1535 - DOI
    1. Honnorat J, Saiz A, Giometto B et al (2001) Cerebellar ataxia with anti–glutamic acid decarboxylase antibodies: study of 14 patients. Arch Neurol 58:225–230 - DOI
    1. Saiz A, Blanco Y, Sabater L et al (2008) Spectrum of neurological syndromes associated with glutamic acid decarboxylase antibodies: diagnostic clues for this association. Brain J Neurol 131:2553–2563 - DOI
    1. Malter MP, Helmstaedter C, Urbach H et al (2010) Antibodies to glutamic acid decarboxylase define a form of limbic encephalitis. Ann Neurol 67:470–478 - DOI
    1. Martinez-Hernandez E, Ariño H, McKeon A et al (2016) Clinical and immunologic investigations in patients with stiff-person spectrum disorder. JAMA Neurol 73:714–720 - DOI

MeSH terms

LinkOut - more resources